Impact of atopy on the severity and extrapulmonary manifestations of childhood Mycoplasma pneumoniae pneumonia

摘要

Objectives The impact of atopy on disease severity and extrapulmonary manifestations in children with Mycoplasma pneumoniae (MP) pneumonia is unknown. Methods Patients diagnosed with MP pneumonia between January 2016, and December 2017, were enrolled in this study. A total of 150 MP pneumonia patients were enrolled at diagnosis and divided into the atopic group (n?=?48) and the nonatopic group (n?=?102). Furthermore, these patients were also assessed after being divided into the pulmonary group (n?=?120) and the extrapulmonary group (n?=?30). Clinical characteristics, respiratory disease severity, any allergy history, and specific allergen sensitizations were collected from all patients. The serum interleukin‐17 (IL‐17) and total immunoglobulin E (lgE) levels were also measured. Results More children in the atopic group than those in the nonatopic group presented with severe MP pneumonia, tachypnea, oxygen therapy, steroid treatment, atopic conditions including asthma attack, a previous history of asthma, decreased IL‐17 levels, and increased IgE levels (all P? Conclusions Atopy may be a risk factor for disease severity and extrapulmonary manifestations in children with MP pneumonia.